Alternatives to Epicrispr Biotechnologies

Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.

Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.

A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.

Clinical-stage biopharmaceutical company leveraging a proprietary platform to discover and develop novel precision medicines from fungi.

Biopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Freenome is a biotechnology company developing a multi-cancer early detection blood test using machine learning and biology.

A biotechnology company developing gene therapy treatments for rare, debilitating genetic diseases.

A biotechnology company developing genetic therapies for rare disorders.

Developing gene editing therapies to lower cholesterol.

Clinical-stage biopharmaceutical company developing novel treatments for exocrine pancreatic insufficiency.

AI-powered drug discovery company focused on neurological and neuromuscular diseases, leveraging transcriptomics to accelerate therapeutic development.

Engineering scalable gene therapies for broader patient populations.

Biotechnology company developing next-generation gene therapies using a proprietary protein splicing platform.

Pioneering vision restoration therapies for severe retinal degenerations.

Developing ultrasound-mediated nonviral genetic medicines.

Developing oral small molecule medicines for immunological and chronic diseases.

Developing novel therapies to reverse aging and extend lifespan.

A clinical-stage biopharmaceutical company developing novel cell therapies for AL Amyloidosis and other serious diseases.

A biopharmaceutical company focused on developing and commercializing therapies for rare diseases.

Developing epigenetic reprogramming drugs for age restoration.

Advancing scalable microbiome-based therapeutics for severe and chronic diseases.

Scalable, one-time curative in-vivo gene editing therapies.

A biopharmaceutical company developing RNA interference (RNAi)-based medicines.

AI-enabled technology for cell biology research and biopharma development.

A commercial-stage immunotherapy company developing novel treatments for cancer and infectious diseases.

Biopharmaceutical company developing best-in-class medicines for autoimmune and rare diseases, with a focus on thyroid eye disease.

Engineering-driven DNA design platform to overcome biological barriers in genetic medicines.

Clinical-stage biotech company developing transformative cytokine therapies.

Developing disease-responsive advanced therapies through programmable gene control technology.

Venture philanthropy organization accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD).

Developing an automated platform for liquid biopsy sample preparation.

Biotechnology company leveraging ultracompact CRISPR systems for gene editing therapies and diagnostics.

Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.

Spatial multiomics company developing technologies for single-cell gene expression profiling in intact tissues.

A vertically-integrated procurement platform for the life sciences industry.

Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.

Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.

A global leader in clinical pharmacology and bioanalytical sciences.

Personalizing cancer care through a novel, physics-informed approach to predict tumor response to therapy.

Developing novel immunotherapies and diagnostics for cancer.

BreezeBio is a genetic medicine company developing a pipeline of precision therapeutics.

A clinical-stage biopharmaceutical company developing novel immunotherapies.

A clinical-stage biopharmaceutical company developing novel therapies for neurological disorders.

A nonprofit research organization leveraging AI and biotechnology to understand and treat complex diseases.

A life sciences company that has developed a high-throughput platform for mapping molecular cell architecture at nanoscale resolution.

Clinical-stage biopharmaceutical company developing next-generation therapies for obesity and cardiometabolic diseases.

A biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension.

Biotechnology company advancing novel therapeutics using its proprietary LEADS drug discovery platform.

The first Integrated Development and Manufacturing Organization (IDMO) for cell therapies.

An end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials, focusing on lung and heart disease.

AI-native biotech company designing next-generation CAR T therapies for solid tumors.

Advancing deupirfenidone as a potential new standard of care for Idiopathic Pulmonary Fibrosis (IPF).

AI-powered antibody discovery platform.

Advancing next-generation mRNA medicines.

Developing a new class of anti-IgE therapy for multiple atopic conditions.

Advancing clinical stage pipeline targeting new and major neurology and neuropsychiatric disorders.

A full-stack spatial biology company.

Provides regulated, secure, and high-yield digital asset solutions for institutional and corporate treasuries.

Unlocking industrial-scale RNA-seq for primary drug screening and toxicology.